Paul Tudor Jones's MLYS Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 155,740 shares of Mineralys Therapeutics, Inc. (MLYS) worth $4.22 M, representing 0.01% of the portfolio. First purchased in 2025-Q4, this recently established position has been held for 2 quarters.
Based on recent 13F filings, Paul Tudor Jones has initiated a new position in MLYS, representing a fresh investment thesis on this company. Largest addition occurred in Q1 2026, adding 116,694 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Mineralys Therapeutics (MLYS) Holding Value Over Time
Track share changes against reported price movement
Quarterly Mineralys Therapeutics (MLYS) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +116,694 | Add 298.86% | 155,740 | $27.09 |
| Q4 2025 | +39,046 | New Buy | 39,046 | $36.29 |
Paul Tudor Jones's Mineralys Therapeutics Investment FAQs
Paul Tudor Jones first purchased Mineralys Therapeutics, Inc. (MLYS) in Q4 2025, acquiring 39,046 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Mineralys Therapeutics, Inc. (MLYS) for 2 quarters since Q4 2025.
Paul Tudor Jones's largest addition to Mineralys Therapeutics, Inc. (MLYS) was in Q1 2026, adding 155,740 shares worth $4.22 M.
According to the latest 13F filing for Q1 2026, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 155,740 shares of Mineralys Therapeutics, Inc. (MLYS), valued at approximately $4.22 M.
As of the Q1 2026 filing, Mineralys Therapeutics, Inc. (MLYS) represents approximately 0.01% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Mineralys Therapeutics, Inc. (MLYS) was 155,740 shares, as reported at the end of Q1 2026.